Lab Reference Library / Fibrinogen
Inflammation & Cardiovascular
Fibrinogen
Fibrinogen · Plasma Fibrinogen · Factor IReference range, optimal functional medicine levels, and why fibrinogen is simultaneously a coagulation factor, a cardiovascular risk marker, and an acute-phase inflammatory protein, and why elevated fibrinogen predicts heart attack, stroke, and deep vein thrombosis independent of cholesterol.
Cardiovascular RiskCoagulation Marker
Standard Range200 to 400 mg/dL
FM Optimal200 to 300 mg/dL
High RiskAbove 400 mg/dL
Unitsmg/dL
← Back to Lab Reference Library
Category: Inflammation & Cardiovascular | Also known as: Plasma Fibrinogen, Factor I, Fibrinogen Level
1. What This Test Measures
Fibrinogen is a soluble plasma glycoprotein produced by the liver that serves as the final substrate in the coagulation cascade. Thrombin cleaves fibrinogen into fibrin monomers that polymerize to form the fibrin clot sealing vascular injury. Beyond coagulation, fibrinogen is a major acute-phase reactant rising significantly during any inflammatory state, and an independent cardiovascular risk factor whose elevation promotes thrombosis, increases blood viscosity, and accelerates atherosclerosis.
Fibrinogen is both a cause and consequence of cardiovascular disease: it rises with inflammation and directly promotes the clotting, viscosity, and plaque progression that drive cardiovascular events. This dual role makes it one of the most clinically informative single markers in a comprehensive cardiovascular risk panel.
2. Optimal Range
| Fibrinogen Level | Interpretation |
|---|---|
| Below 200 mg/dL | Low: check for liver disease or disseminated intravascular coagulation |
| 200 to 300 mg/dL | Optimal: lowest cardiovascular and thrombotic risk |
| 300 to 400 mg/dL | Borderline elevated: meaningful risk increment; active intervention warranted |
| Above 400 mg/dL | Elevated: significantly increased cardiovascular event and VTE risk |
| Above 500 mg/dL | Markedly elevated: aggressive investigation and management |
Fibrinogen is an acute-phase reactant: it rises with any acute infection, injury, or inflammatory flare. For cardiovascular risk assessment, draw during stable health and not within 2 to 3 weeks of acute illness. Women on estrogen-containing contraceptives or hormone replacement therapy have fibrinogen levels 10 to 20% above baseline. Pregnancy substantially elevates fibrinogen.
3. Why Elevated Fibrinogen Increases Cardiovascular Risk
- Direct thrombosis promotion: fibrinogen is the immediate clot-forming substrate; elevated levels produce a denser fibrin network with reduced susceptibility to fibrinolysis (thrombolysis), creating clots that are harder to dissolve once formed at sites of plaque rupture
- Increased blood viscosity: fibrinogen is the dominant determinant of plasma viscosity; elevated fibrinogen raises blood viscosity, increasing shear stress on arterial walls, reducing microvascular flow, and promoting endothelial injury
- Platelet aggregation enhancement: fibrinogen bridges activated platelets through glycoprotein IIb/IIIa receptors; elevated fibrinogen amplifies platelet-mediated thrombosis
- Atherosclerotic plaque incorporation: fibrinogen and fibrin are incorporated into atherosclerotic plaques, contributing to plaque growth and smooth muscle cell proliferation
- Inflammatory signal: fibrinogen elevation reflects the chronic inflammatory milieu that drives atherosclerosis at multiple stages
- Venous thromboembolism: elevated fibrinogen independently predicts DVT and pulmonary embolism, providing an additional reason to target lower fibrinogen in patients with thrombotic history
4. What Causes Elevated Fibrinogen
- Smoking: one of the most potent fibrinogen elevators; raises fibrinogen by 20 to 40%; the fibrinogen-raising effect of smoking is a major mechanism of smoking's cardiovascular toxicity
- Metabolic syndrome and insulin resistance: visceral adiposity produces IL-6 which stimulates hepatic fibrinogen synthesis; metabolic syndrome consistently elevates fibrinogen alongside hs-CRP
- Obesity: directly correlated with fibrinogen through IL-6 and other adipose-derived inflammatory cytokines
- Diabetes: elevated fibrinogen is nearly universal in type 2 diabetes and contributes to the dramatically elevated cardiovascular and thrombotic risk of the diabetic state
- Chronic infection and inflammation: any persistent inflammatory source including periodontal disease, H. pylori, sleep apnea, and autoimmune disease elevates fibrinogen
- Estrogen: oral contraceptives and postmenopausal hormone replacement raise fibrinogen by 10 to 20%; this is one mechanism of the increased VTE risk associated with estrogen use
- Sedentary lifestyle: physical inactivity is independently associated with elevated fibrinogen; exercise consistently reduces fibrinogen
- Aging: fibrinogen rises progressively with age independent of other risk factors
5. How to Lower Fibrinogen
Lifestyle
- Smoking cessation: the single most impactful intervention; reduces fibrinogen by 15 to 30% within 3 to 6 months of cessation
- Regular aerobic exercise: 150 minutes per week consistently reduces fibrinogen by 10 to 20%; mechanism involves reduced IL-6 production from visceral fat and improved fibrinolytic activity
- Weight loss targeting visceral fat: visceral adipose is the primary IL-6 source driving fibrinogen; 5 to 10% body weight loss reduces fibrinogen proportionally
- Treat periodontal disease: oral bacteria chronically activate systemic coagulation and elevate fibrinogen; treatment reduces fibrinogen by 15 to 25%
- Treat obstructive sleep apnea: CPAP therapy reduces fibrinogen in sleep apnea patients
Nutrition
- Omega-3 fatty acids (2 to 4g EPA and DHA daily): reduces fibrinogen by 10 to 20% through anti-inflammatory and anti-platelet mechanisms; one of the most evidence-based nutritional interventions for fibrinogen lowering
- Mediterranean diet: consistently associated with lower fibrinogen in epidemiological and intervention studies; high in anti-inflammatory polyphenols, fiber, and omega-3 fats
- Nattokinase (the fibrinolytic enzyme from natto fermentation): fibrin-specific protease that directly degrades fibrin clots and reduces serum fibrinogen; 2,000 to 4,000 FU daily
- Lumbrokinase: earthworm-derived fibrinolytic enzyme; similar mechanism to nattokinase; used in some integrative protocols for elevated fibrinogen
- Reduce refined carbohydrates and added sugar: metabolic syndrome-driven fibrinogen responds to insulin resistance correction
Medical Options
- Statin therapy: reduces fibrinogen by 10 to 20% through pleiotropic anti-inflammatory effects; the fibrinogen-lowering effect contributes to statins' cardiovascular event reduction beyond LDL lowering
- Fibrate therapy (fenofibrate, gemfibrozil): reduces fibrinogen by 20 to 30%; used primarily in hypertriglyceridemia but the fibrinogen-lowering effect is a cardiovascular benefit
- Niacin: reduces fibrinogen by 10 to 25%; one of the most comprehensive lipid and coagulation risk-modifying agents
- Aspirin: does not lower fibrinogen but addresses the platelet aggregation mechanism that elevated fibrinogen amplifies
- Address underlying inflammatory conditions: autoimmune disease, uncontrolled diabetes, and chronic infections driving fibrinogen elevation require primary treatment
6. Related Lab Tests
hs-CRPBoth Rise with Inflammation; Complementary Risk Markers
→
ApoBCombined Elevated ApoB and Fibrinogen is Very High Risk
→
HomocysteineProthrombotic Risk Companion Marker
→
Omega-3 IndexOmega-3s Lower Fibrinogen and Platelet Aggregation
→
Lipoprotein(a)Both Impair Fibrinolysis; Combined Risk
→
TG/HDL RatioMetabolic Syndrome Context for Fibrinogen Elevation
→
7. Clinical Perspective
Clinical Perspective
Fibrinogen is the marker that completes my cardiovascular risk picture because it captures both the inflammatory burden and the prothrombotic state simultaneously. A patient with ApoB of 88, hs-CRP of 2.4, and fibrinogen of 487 mg/dL is not just an inflammatory risk patient; they are a patient whose blood is literally thicker and more clot-prone than it should be, and whose clots, if they form at a plaque rupture site, will be denser and harder to lyse than normal. The combination of elevated fibrinogen with elevated Lp(a) is the pattern I find most concerning for thrombotic cardiovascular events, because both independently impair fibrinolysis through different mechanisms. Omega-3s, nattokinase, and smoking cessation are the interventions I reach for first when fibrinogen is the dominant risk signal, alongside addressing the underlying inflammatory drivers.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
8. Frequently Asked Questions
What is the optimal fibrinogen level?
In functional medicine, optimal fibrinogen is 200 to 300 mg/dL. The standard reference range of 200 to 400 mg/dL allows values that carry meaningful cardiovascular risk. Multiple large studies demonstrate continuous risk elevation above 300 mg/dL, with the Prospective Studies Collaboration finding approximately 2-fold elevated coronary heart disease risk in the top versus bottom tertile of fibrinogen.
What causes elevated fibrinogen?
Fibrinogen is a major acute-phase reactant that rises with any source of systemic inflammation. The most common drivers are smoking (20 to 40% elevation), obesity and metabolic syndrome (IL-6-driven hepatic synthesis), diabetes, chronic infections including periodontal disease, estrogen-containing medications, sedentary lifestyle, and aging. Draw during stable health for cardiovascular risk assessment.
Why does elevated fibrinogen increase cardiovascular risk?
Elevated fibrinogen promotes cardiovascular risk through: direct thrombosis promotion (it is the clot-forming substrate; elevated levels produce denser, harder-to-dissolve clots), increased blood viscosity, enhanced platelet aggregation, incorporation into atherosclerotic plaques, and as a marker of the underlying chronic inflammation driving all of these processes.
How do you lower fibrinogen?
The most effective interventions are: smoking cessation (15 to 30% reduction), regular aerobic exercise (10 to 20%), omega-3 fatty acids at 2 to 4g EPA and DHA daily (10 to 20%), nattokinase supplementation, statin therapy (10 to 20%), fibrate therapy (20 to 30%), weight loss targeting visceral fat, treating periodontal disease, and Mediterranean diet pattern.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Fibrinogen above 400 mg/dL means thicker blood, denser clots, and a cardiovascular event risk that your cholesterol panel cannot see.
Fibrinogen is the prothrombotic and inflammatory cardiovascular risk marker most clinicians never order. Schedule a consultation for a complete advanced cardiovascular risk assessment.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.